ABSTRACT
Thirty four patients with mild to moderate hypertension, were put on benidipine 4 mg/day after two weeks of placebo therapy. Twenty five patients completed the trial successfully for 4 mg benidipine. The blood pressure of 20 patients was controlled with benidipine 4 mg/day (effective rate 80%). Five patients with unsatisfactory control on 4 mg/day benidipine were put on 8 mg/day. Four of them were controlled and one was considered as failure (effective rate 80%). Most of the patients tolerated the drug well. Three patients had mild side effects like headache and heaviness in the head. One of them also had puffiness of face and body (on benidipine 8 mg/day) and was withdrawn from the study. One patient had mild constipation. We conclude that benidipine is well tolerated in the dose of 4-8 mg/day and is an effective antihypertensive agent for treatment of patients with mild to moderate hypertension.
Subject(s)
Adult , Aged , Blood Pressure Determination , Calcium Channel Blockers/administration & dosage , Dihydropyridines/administration & dosage , Dose-Response Relationship, Drug , Drug Administration Schedule , Female , Follow-Up Studies , Humans , Hypertension/diagnosis , Male , Middle Aged , Reference Values , Severity of Illness Index , Treatment OutcomeABSTRACT
Iron deficiency occurs when the rate of loss of utilization exceeds its assimilation. Treatment is based on iron supplementation but due to side effects compliance to iron therapy is poor. A double blind comparative study was done using a novel time release preparation of ferrous sulphate (Code A) v.s. sustained release ferrous sulphate preparation (Code B) on 60 pregnant women in mid or late pregnancy with anaemia. The amount of ferrous sulphate in Code A was less than half of Code B. The patients were sequentially randomised as Code A or Code B recipient. The non compliance rate was 33%, and for both Code A & Code B. The mean improvement in hemoglobin after 4 weeks of therapy was 2.01 gm% for Code A and 2.3 gm% for Code B. Iron absorption as evidenced by improvement in S. Iron, TIBC and ferritin levels was better with Code A. The improvement in subjective symptoms of anaemia was better than average in Code B preparation. Code A group had comparatively more side effects both major and minor, this may have been the reason for a slightly higher drop out rate in this group. In conclusion the timed release preparation has a comparable haematological response and better absorption with significantly lower doses as compared to the sustained release preparation.